1. Home
  2. SECZ vs ANNX Comparison

SECZ vs ANNX Comparison

Compare SECZ & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Securitize Corp.

SECZ

Securitize Corp.

N/A

Current Price

$8.04

Market Cap

1.0B

Sector

N/A

ML Signal

N/A

Logo Annexon Inc.

ANNX

Annexon Inc.

HOLD

Current Price

$4.14

Market Cap

873.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SECZ
ANNX
Founded
N/A
2011
Country
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
873.3M
IPO Year
2026
2020

Fundamental Metrics

Financial Performance
Metric
SECZ
ANNX
Price
$8.04
$4.14
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$16.50
AVG Volume (30 Days)
2.2M
2.5M
Earning Date
N/A
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$16,320.74
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.14
$2.32
52 Week High
$13.20
$7.18

Technical Indicators

Market Signals
Indicator
SECZ
ANNX
Relative Strength Index (RSI) 56.63 27.78
Support Level $6.15 $4.01
Resistance Level $8.01 $5.63
Average True Range (ATR) 0.58 0.24
MACD 0.28 -0.08
Stochastic Oscillator 71.41 6.64

Price Performance

Historical Comparison
SECZ
ANNX

About SECZ Securitize Corp.

Securitize Holdings Inc provides a platform for tokenized real-world assets specializing in tokenizing real-world assets (RWAs) like funds, equities, and fixed income on blockchain networks. The company operates across two primary verticals: i) Tokenization: It consists of on-chain infrastructure and tokenization & distribution, ii) Asset Servicing: It covers post-issuance transfer agent and fund management services. The majority of the company's revenue is derived from the Tokenization vertical.

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Share on Social Networks: